MEDOVEX CORP. (NASDAQ:MDVX) Files An 8-K Regulation FD Disclosure

On February 15, 2017, MedoveX Corp. (the Company) issued a press
release (the Release) regarding the status of its CE Mark
approval.A copy of the Release is attached hereto and
incorporated herein by reference in its entirety as Exhibit 99.1.

The information contained in this Current Report on Form 8-K
shall not be deemed filed for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the Exchange Act),
or incorporated by reference in any filing under the Securities
Act of 1933, as amended (the Securities Act) or the Exchange Act,
except as shall be expressly set forth by specific reference in
such a filing.The furnishing of the information in this Current
Report on Form 8-K is not intended to, and does not, constitute a
representation that such furnishing is required by Regulation FD
or that the information contained in this Current Report on Form
8-K constitutes material investor information that is not
otherwise publicly available.

The Securities and Exchange Commission encourages registrants to
disclose forward-looking information so that investors can better
understand the future prospects of a registrant and make informed
investment decisions. This Current Report on Form 8-K and
exhibits may contain these types of statements, which are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, and which involve
risks, uncertainties and reflect the Registrants judgment as of
the date of this Current Report on Form 8-K. Forward-looking
statements may relate to, among other things, operating results
and are indicated by words or phrases such as expects, should,
will, and similar words or phrases. These statements are subject
to inherent uncertainties and risks that could cause actual
results to differ materially from those anticipated at the date
of this Current Report on Form 8-K. Investors are cautioned not
to rely unduly on forward-looking statements when evaluating the
information presented within.

Item 9.01Financial Statements and Exhibits

(d)Exhibits.

Exhibit No.		Description
99.1		Press Release dated February 15, 2017